NCT01545427View on ClinicalTrials.gov

Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma

PHASE2TerminatedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Scleroderma

Interventions

DRUG

Imatinib mesylate

200 mg bid for 6 months

OTHER

Placebo

Placebo coated to match appearance of Gleevec identically.

Trial Locations (1)

N6A 4V2

Lawson Health Research Institute, London

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER